Fortress Biotech, Inc.
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
News
Fortress Biotech, Inc. (NASDAQ:FBIO) is not putting all its eggs in one basket. This is a biopharmaceutical company with multiple revenue streams and a profuse product portfolio so diversified that Harry Markowitz, the father of modern portfolio theory, might tip his hat to the way the company has sought to mitigate developmental risks. Fortress' diverse product pipeline also gives it multiple shots at hitting its financial goals, increased by the symbiotic relationship between development areas. The research platforms are structured so that success in one area is likely to add impetus to another.
###
586 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 5) (Last 30 Days: 17) (Since Published: 586)
